New Leadership and Focus on Advancement of IkT-001 into a Late-Stage Clinical Trial Program in Pulmonary Arterial ...

KalVista Pharmaceuticals has finished enrolling subjects in its KONFIDENT-KID trial of sebetralstat for hereditary angioedema ...

Results from the company’s Phase II trial also saw PL8177 elicit a clinical response in 77% of ulcerative colitis patients.

Acumen Pharmaceuticals has concluded enrolment for its multi-centre, double-blind Phase II ALTITUDE-AD trial of humanised ...

Q4 2024 Earnings Call Transcript March 17, 2025 Operator: Good morning, ladies and gentlemen, and welcome to the NRx ...

Pfizer placed a $6.7 billion bet on the outcome of two phase 3 trials of Arena Pharmaceuticals' etrasimod in ulcerative colitis (UC) when it acquired the company earlier this year, and the gamble ...

Led by alums from Takeda and Boston Pharmaceuticals, Hillstar Bio is working on treatments that remove harmful immune cells to relieve disease.

Research in mice identifies protein responsible for regulating gut movement in response to pressure, exercise, and ...

After every meal, the intestines perform an action called peristalsis - moving food through their hollow interiors with coordinated contractions and relaxations of the smooth muscle.

Novartis was announced as an official partner of this year’s Eurovision competition last fall, after the song entry from ...

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) is a commercial-stage biopharmaceutical company specializing in developing and commercializing treatments for rare neurological and neuromuscular diseases.

Benchmark indices Sensex and Nifty ended their seven-day winning streak on Wednesday, falling nearly 1% due to profit-booking ...